Related Experiment Video
Updated: Jan 30, 2026
05:05
Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
Published on: November 4, 2011
21.6K
Abstract:
The FDA greenlighted 17 novel cancer agents in 2018, including one with a novel endpoint in a clinical trial and one through an expanded access program. The agency also approved five biosimilars to treat cancer or the side effects of treatment.
Insights
In 2018, the FDA approved 17 new cancer drugs, including innovative treatments and five biosimilars. These advancements offer new options for cancer patients and improve treatment accessibility.
Area of Science:
- Oncology
- Drug Development
- Regulatory Science
Background:
- In 2018, the U.S. Food and Drug Administration (FDA) demonstrated significant activity in advancing cancer therapeutics.
- The agency's approvals included novel agents and biosimilars, reflecting progress in cancer treatment and drug evaluation.
Discussion:
- The FDA's 2018 approvals encompassed 17 novel cancer agents, highlighting innovation in drug discovery and development.
- Notably, one agent utilized a novel endpoint in its clinical trial, signifying evolving trial methodologies.
- Another agent was approved via an expanded access program, broadening patient access to investigational therapies.
Key Insights:
- The FDA authorized five biosimilar products in 2018, offering more treatment options for cancer and its associated side effects.
- These approvals underscore the growing availability and acceptance of biosimilars in oncology.
- The diverse range of approvals indicates a dynamic landscape for cancer drug development and regulatory review.
Outlook:
- The 2018 approvals set a precedent for continued innovation and accessibility in cancer treatment.
- Future trends may involve further development of novel endpoints and expanded use of biosimilars.
- Ongoing regulatory efforts are crucial for ensuring timely access to effective cancer therapies.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
268
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
268
01:19Precipitation Titration: Endpoint Detection Methods
6.0K
In argentometric precipitation titrations, endpoints can be detected visually by the Mohr, Volhard, and Fajans methods. In the Mohr method, adding a soluble chromate indicator gives an initial yellow color to the analyte solution. As the titrant is added, the first excess of silver ions forms a red silver chromate precipitate, marking the endpoint. The solution pH should be maintained at about 8 by adding solid CaCO3.
In the Volhard method, a standard excess of AgNO3 is first added to the...
In the Volhard method, a standard excess of AgNO3 is first added to the...
6.0K
01:25Pharmacokinetics: Drug–Drug Interactions
435
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
435
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
157
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
157
01:27Factors Influencing Drug Absorption: Drug Dissolution
1.2K
The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
1.2K
01:18Factors Affecting Protein-Drug Binding: Drug-Related Factors
479
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
479